Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to $57.8 million.

  • Axsome Therapeutics' Cash from Financing Activities fell 30.05% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.3 million, marking a year-over-year increase of 127.84%. This contributed to the annual value of $57.8 million for FY2024, which is 82.53% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Cash from Financing Activities of $57.8 million as of FY2024, which was down 82.53% from $331.0 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Cash from Financing Activities ranged from a high of $331.0 million in FY2023 and a low of $11.1 million during FY2021.
  • In the last 3 years, Axsome Therapeutics' Cash from Financing Activities had a median value of $284.6 million in 2022 and averaged $224.5 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Cash from Financing Activities slumped by 83.20% in 2020, and later soared by 2,456.89% in 2022.
  • Yearly analysis of 5 years shows Axsome Therapeutics' Cash from Financing Activities stood at $42.4 million in 2020, then crashed by 73.76% to $11.1 million in 2021, then surged by 2,456.89% to $284.6 million in 2022, then rose by 16.32% to $331.0 million in 2023, then plummeted by 82.53% to $57.8 million in 2024.